MX2022013396A - Compuestos de tetrahidroisoquinolina como activadores de nrf2. - Google Patents
Compuestos de tetrahidroisoquinolina como activadores de nrf2.Info
- Publication number
- MX2022013396A MX2022013396A MX2022013396A MX2022013396A MX2022013396A MX 2022013396 A MX2022013396 A MX 2022013396A MX 2022013396 A MX2022013396 A MX 2022013396A MX 2022013396 A MX2022013396 A MX 2022013396A MX 2022013396 A MX2022013396 A MX 2022013396A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- nrf2 activators
- tetrahydroisoquinoline compounds
- nrf2
- activators
- Prior art date
Links
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 title abstract 3
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 title abstract 3
- 239000012190 activator Substances 0.000 title abstract 2
- 125000003039 tetrahydroisoquinolinyl group Chemical class C1(NCCC2=CC=CC=C12)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000004913 activation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a compuestos que son activadores de Nrf2. Los compuestos tienen la fórmula estructural I definida en la presente. La presente invención también se refiere a procesos para la preparación de estos compuestos, a composiciones farmacéuticas que los comprenden y a su uso en el tratamiento de enfermedades o trastornos asociados con la activación de Nrf2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2005852.5A GB202005852D0 (en) | 2020-04-22 | 2020-04-22 | Therapeutic compounds |
| PCT/GB2021/050975 WO2021214472A1 (en) | 2020-04-22 | 2021-04-22 | Tetrahydroisoquinoline compounds as nrf2 activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022013396A true MX2022013396A (es) | 2022-12-13 |
Family
ID=70859963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022013396A MX2022013396A (es) | 2020-04-22 | 2021-04-22 | Compuestos de tetrahidroisoquinolina como activadores de nrf2. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230159511A1 (es) |
| EP (1) | EP4139295B1 (es) |
| JP (1) | JP7751165B2 (es) |
| KR (1) | KR20230004722A (es) |
| CN (1) | CN115667242B (es) |
| AR (1) | AR121913A1 (es) |
| AU (1) | AU2021258539A1 (es) |
| BR (1) | BR112022021370A2 (es) |
| CA (1) | CA3174360A1 (es) |
| ES (1) | ES3031970T3 (es) |
| GB (1) | GB202005852D0 (es) |
| IL (1) | IL297440A (es) |
| MX (1) | MX2022013396A (es) |
| PH (1) | PH12022552773A1 (es) |
| WO (1) | WO2021214472A1 (es) |
| ZA (1) | ZA202211464B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY207469A (en) * | 2018-10-22 | 2025-02-27 | C4X Discovery Ltd | Therapeutic compounds |
| EP4423079A1 (en) | 2021-10-25 | 2024-09-04 | C4X Discovery Limited | Tetrahydroisoquinoline compounds that are keap1 binders |
| WO2024130411A1 (en) * | 2022-12-21 | 2024-06-27 | Variational Ai Inc. | Protease inhibitors and methods of using same |
| WO2024262491A1 (ja) * | 2023-06-19 | 2024-12-26 | 中外製薬株式会社 | Ｎｒｆ２活性化作用を有する含窒素複素環化合物の結晶 |
| EP4596534A1 (en) * | 2024-01-31 | 2025-08-06 | University of Copenhagen | Noncovalent small-molecule inhibitors of the keap1-nrf2 interaction |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013067036A1 (en) * | 2011-10-31 | 2013-05-10 | Rutgers, The State University Of New Jersey | Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators |
| CN107709306A (zh) * | 2015-06-15 | 2018-02-16 | 葛兰素史密斯克莱知识产权发展有限公司 | Nrf2调节剂 |
| JP2020097526A (ja) * | 2017-03-28 | 2020-06-25 | 武田薬品工業株式会社 | 複素環化合物 |
| MY207469A (en) | 2018-10-22 | 2025-02-27 | C4X Discovery Ltd | Therapeutic compounds |
-
2020
- 2020-04-22 GB GBGB2005852.5A patent/GB202005852D0/en not_active Ceased
-
2021
- 2021-04-22 PH PH1/2022/552773A patent/PH12022552773A1/en unknown
- 2021-04-22 CA CA3174360A patent/CA3174360A1/en active Pending
- 2021-04-22 US US17/920,244 patent/US20230159511A1/en active Pending
- 2021-04-22 KR KR1020227040564A patent/KR20230004722A/ko active Pending
- 2021-04-22 EP EP21724005.0A patent/EP4139295B1/en active Active
- 2021-04-22 AU AU2021258539A patent/AU2021258539A1/en active Pending
- 2021-04-22 WO PCT/GB2021/050975 patent/WO2021214472A1/en not_active Ceased
- 2021-04-22 BR BR112022021370A patent/BR112022021370A2/pt unknown
- 2021-04-22 ES ES21724005T patent/ES3031970T3/es active Active
- 2021-04-22 IL IL297440A patent/IL297440A/en unknown
- 2021-04-22 CN CN202180030434.4A patent/CN115667242B/zh active Active
- 2021-04-22 JP JP2022564532A patent/JP7751165B2/ja active Active
- 2021-04-22 AR ARP210101081A patent/AR121913A1/es unknown
- 2021-04-22 MX MX2022013396A patent/MX2022013396A/es unknown
-
2022
- 2022-10-19 ZA ZA2022/11464A patent/ZA202211464B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4139295B1 (en) | 2025-04-09 |
| KR20230004722A (ko) | 2023-01-06 |
| IL297440A (en) | 2022-12-01 |
| PH12022552773A1 (en) | 2024-03-25 |
| CA3174360A1 (en) | 2021-10-28 |
| JP7751165B2 (ja) | 2025-10-08 |
| AR121913A1 (es) | 2022-07-20 |
| WO2021214472A1 (en) | 2021-10-28 |
| CN115667242B (zh) | 2025-02-28 |
| US20230159511A1 (en) | 2023-05-25 |
| ZA202211464B (en) | 2025-05-28 |
| ES3031970T3 (en) | 2025-07-14 |
| EP4139295A1 (en) | 2023-03-01 |
| GB202005852D0 (en) | 2020-06-03 |
| AU2021258539A1 (en) | 2022-11-10 |
| BR112022021370A2 (pt) | 2022-12-06 |
| JP2023524207A (ja) | 2023-06-09 |
| CN115667242A (zh) | 2023-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022013396A (es) | Compuestos de tetrahidroisoquinolina como activadores de nrf2. | |
| MX2021004566A (es) | Compuestos terapeuticos. | |
| ECSP24035717A (es) | Compuestos de quinolina como inhibidores de kras | |
| CO2022016899A2 (es) | Moduladores de il-17a | |
| CO2022010241A2 (es) | Inhibidores de sos1 | |
| CO2022018636A2 (es) | Moduladores de il-17a | |
| CL2019002255A1 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas. | |
| CL2019001658A1 (es) | Derivados de la pirimidin enona tricíclica para la inhibición de rory y otros usos. | |
| CU20190101A7 (es) | Imidazopirimidinas diazabicíclicas sustituidas | |
| UY35293A (es) | Isotiazoles sustituidos con amino | |
| ECSP23076906A (es) | Composiciones y métodos para inhibir cetohexoquinasa (khk) | |
| CO2017007325A2 (es) | 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos | |
| DOP2018000238A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
| MX383520B (es) | Nuevos compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor | |
| MX2019012522A (es) | Compuestos y metodos terapeuticos. | |
| CO2019002523A2 (es) | Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica | |
| MX2021002916A (es) | Pirfenidona enriquecida con deuterio y métodos para su uso. | |
| CO2024005925A2 (es) | Moléculas pequeñas para el tratamiento del cáncer | |
| CL2024001565A1 (es) | Compuestos macrocíclicos con actividad inhibidora de la farnesiltransferasa, composición que los comprende y su uso. | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| MX2022013398A (es) | Compuestos de tetrahidroisoquinolina como activadores de nrf2. | |
| CL2021000282A1 (es) | Inhibidores de ckd8/19 | |
| MX2022003398A (es) | Composicion micelar inmunoestimulante. | |
| MX2021008748A (es) | Derivados de aminoacidos para el tratamiento de enfermedades inflamatorias. | |
| ECSP22093652A (es) | Compuestos de imidazopiridazina y usos de los mismos |